Literature DB >> 16629424

Treatment of depression for patients with multiple sclerosis in neurology clinics.

D C Mohr1, S L Hart, I Fonareva, E S Tasch.   

Abstract

UNLABELLED: The objective of this study was to examine the adequacy of antidepressant pharmacotherapy in a sample of patients with multiple sclerosis (MS) treated by neurologists.
METHODS: MS patients under the care of neurologists were recruited from a large health maintenance organization. Major depressive disorder (MDD) was diagnosed using a structured telephone interview. Antidepressant treatment data were obtained from the HMO pharmacy database.
RESULTS: Study participants included 260 patients with MS treated by 35 neurologists. A total of 67 (25.8%) patients met the criteria for MDD. Among the patients with MDD, 65.6% received no antidepressant medication, 4.7% received subthreshold doses from their neurologists, 26.6% received doses at threshold, and 3.1% received doses exceeding threshold. DISCUSSION: Depression was undertreated by the neurologists treating this sample of patients with comorbid MS and MDD. Potential solutions are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629424     DOI: 10.1191/135248506ms1265oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  29 in total

Review 1.  [Adherence to neurologic treatment. Lessons from multiple sclerosis].

Authors:  S Kern; H Reichmann; T Ziemssen
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

2.  Longitudinal changes in quality of life and related psychosocial variables in australians with multiple sclerosis.

Authors:  Judy Ann Wollin; Nancy Spencer; Elizabeth McDonald; Gary Fulcher; Maureen Bourne; Rex D Simmons
Journal:  Int J MS Care       Date:  2013

3.  Relationship between disease-modifying therapy and depression in multiple sclerosis.

Authors:  Stephen S Kirzinger; Jason Jones; Angela Siegwald; Andrew Bryce Crush
Journal:  Int J MS Care       Date:  2013

4.  Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.

Authors:  Antonios Bayas; Katrin Schuh; Monika Baier; Stefan Viktor Vormfelde
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

5.  Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions.

Authors:  Adrianna Ratajska; Jonathan Zurawski; Brian Healy; Bonnie I Glanz
Journal:  Int J MS Care       Date:  2019 May-Jun

Review 6.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

7.  Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite.

Authors:  Kimia Honarmand; Nadine Akbar; Nancy Kou; Anthony Feinstein
Journal:  J Neurol       Date:  2010-09-12       Impact factor: 4.849

Review 8.  Co-occurring depression and pain in multiple sclerosis.

Authors:  Kevin N Alschuler; Dawn M Ehde; Mark P Jensen
Journal:  Phys Med Rehabil Clin N Am       Date:  2013-07-23       Impact factor: 1.784

9.  Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life.

Authors:  Mariam Hanna; Lauren Beth Strober
Journal:  Mult Scler Relat Disord       Date:  2020-06-06       Impact factor: 4.339

10.  The relevance of depressive symptoms and social support to disability in women with multiple sclerosis or fibromyalgia.

Authors:  Lorraine J Phillips; Alexa K Stuifbergen
Journal:  Int J Rehabil Res       Date:  2010-06       Impact factor: 1.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.